Cabaletta Bio (CABA) Projected to Release Earnings on Thursday

Cabaletta Bio (NASDAQ:CABA) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to post earnings of ($0.37) per share and revenue of $1.6670 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 7, 2026 at 9:30 AM ET.

Cabaletta Bio (NASDAQ:CABA) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.02. On average, analysts expect Cabaletta Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cabaletta Bio Stock Performance

NASDAQ CABA opened at $2.62 on Thursday. Cabaletta Bio has a 52-week low of $1.26 and a 52-week high of $4.23. The company has a fifty day moving average of $3.10 and a 200-day moving average of $3.03. The company has a market capitalization of $427.19 million, a P/E ratio of -1.34 and a beta of 3.26.

Institutional Trading of Cabaletta Bio

Hedge funds have recently added to or reduced their stakes in the business. Comerica Bank boosted its position in Cabaletta Bio by 2,292.1% during the first quarter. Comerica Bank now owns 41,599 shares of the company’s stock valued at $58,000 after buying an additional 39,860 shares during the period. Mercer Global Advisors Inc. ADV purchased a new position in shares of Cabaletta Bio in the fourth quarter worth about $58,000. Tower Research Capital LLC TRC lifted its stake in shares of Cabaletta Bio by 695.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 51,036 shares of the company’s stock valued at $78,000 after acquiring an additional 44,621 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Cabaletta Bio by 357.1% in the 1st quarter. Invesco Ltd. now owns 61,675 shares of the company’s stock valued at $85,000 after acquiring an additional 48,181 shares during the last quarter. Finally, LPL Financial LLC purchased a new stake in Cabaletta Bio during the 4th quarter valued at about $93,000.

Wall Street Analysts Forecast Growth

CABA has been the topic of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Cabaletta Bio in a research report on Friday, July 17th. Wall Street Zen lowered Cabaletta Bio from a “hold” rating to a “sell” rating in a research report on Saturday, June 13th. Jefferies Financial Group reissued a “buy” rating on shares of Cabaletta Bio in a report on Wednesday, June 3rd. Wells Fargo & Company boosted their target price on Cabaletta Bio from $2.00 to $4.00 and gave the stock an “equal weight” rating in a research report on Friday, May 15th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $30.00 target price on shares of Cabaletta Bio in a research note on Monday, May 4th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.50.

Cabaletta Bio Company Profile

Cabaletta Bio is a clinical-stage biotechnology company pioneering chimeric autoantibody receptor T cell (CAAR-T) therapies for B cell–mediated autoimmune diseases. Its proprietary platform engineers patient-derived T cells to selectively target and eliminate pathogenic B cells that produce disease-driving autoantibodies, with the aim of preserving overall immune function and reducing off-target toxicity.

The company’s lead candidate, DSG3-CAART, is being evaluated in pemphigus vulgaris, a rare blistering disorder caused by autoantibodies against desmoglein 3.